Market Overview

Rib-X Pharmaceuticals' RX-04 Program will be featured at Windhover's Therapeutic Area Partnerships Meeting as a "Top 10 Infectious Diseases Project to Watch"

NEW HAVEN, Conn.--(BUSINESS WIRE)--

Rib-X Pharmaceuticals, Inc. announced today that the Company's RX-04 program has been selected by Windhover Information as one of the “Top 10 Infectious Diseases Projects to Watch.” RX-04 is Rib-X's most advanced preclinical program focused on using a discrete, novel binding site within the bacterial ribosome to design and develop completely new classes of antibiotics to treat some of the most deadly and difficult-to-treat, multi-drug resistant Gram-positive and Gram-negative infections. Data recently presented at ICAAC 2012 demonstrated the unique activity of RX-04 compounds across a diverse array of bacterial pathogens including against carbapenem- and colistin-resistant strains of Klebsiella pneumoniae and major biodefense pathogens.

As part of this recognition, Erin Duffy, Ph.D., Chief Scientific Officer of Rib-X, will present an overview of RX-04 at Windhover's Therapeutic Area Partnerships meeting taking place on November 28 - 30, 2012, at the Westin Copley Boston. Dr. Duffy's presentation will take place on Thursday, November 29 at 4:20 p.m. Eastern Time.

“The Top 10 Infectious Diseases Projects to Watch” were selected using various criteria, including market size and medical need, development history, supporting science, the diversity of potential indications and multi-level partnering opportunities.

About the RX-04 Program

The RX-04 compounds bind to a novel site on the ribosome that has never before been exploited by marketed antibiotics and have proprietary chemical characteristics distinct from all current classes of broad-spectrum or Gram-negative therapies. Since its unveiling at ICAAC 2011, the RX-04 program has progressed to late lead optimization. In June, 2011, Rib-X signed a collaborative and licensing agreement with Sanofi, giving Sanofi the right to develop multiple product candidates targeting this distinct binding site within the ribosome.

Based on preclinical data and on studies published in Antimicrobial Agents and Chemotherapy, RX-04 is believed to be the only drug development program that has produced compounds with demonstrated in vitro coverage of all of the following multi-drug resistant Gram-positive bacteria: Enterococci, Streptococci and Staphylococci, including MRSA; and multi-drug resistant and extremely drug resistant Gram-negative bacteria: Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli. These pathogens account for a majority of hospital-acquired infections, are associated with high rates of morbidity and mortality and are increasingly multi-drug resistant, meaning that they are resistant to more than three classes of antibiotics. Rib-X has shown that the activity of these compounds is unaffected by cross-resistance to current therapies, and lower resistance development is expected compared to current therapies. These compounds are also small molecules, thereby providing the potential to ultimately offer an IV-to-oral switch for maximum flexibility.

About Rib-X:

Rib-X Pharmaceuticals, Inc. is a biopharmaceutical company developing new antibiotics to provide superior coverage, safety and convenience for the treatment of serious and life-threatening infections. The Company's proprietary drug discovery platform provides an atomic-level, three-dimensional understanding of interactions between drug candidates and their bacterial targets and enables design of antibiotics with enhanced characteristics. Rib-X has two antibiotic candidates in clinical development. Delafloxacin is an enhanced spectrum IV/oral antibiotic intended for use as first-line monotherapy primarily in hospitals and recently completed a Phase 2b clinical trial for the treatment of acute bacterial skin and skin structure infections. Radezolid is a next-generation IV/oral oxazolidinone designed to be a potent antibiotic with a safety profile permitting long-term treatment of resistant infections. The Company's pipeline also includes its preclinical RX-04 program, partnered with Sanofi, S.A., and other discovery stage anti-infective programs.

For more information, please visit www.rib-x.com

Company
Rib-X Pharmaceuticals, Inc.
Bob Conerly, 203-624-5606
bconerly@rib-x.com
or
Media Relations
For Rib-X Pharmaceuticals, Inc.
Kari Watson, 781-235-3060
kwatson@macbiocom.com

 

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters